| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Richard M Ransohoff | Q87833085 |
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 2622-2629 | |
| P577 | publication date | 2007-06-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Natalizumab for multiple sclerosis | |
| P478 | volume | 356 |
| Q37862062 | A critical appraisal of treatment decisions in multiple sclerosis--old versus new. |
| Q58807974 | A new player in lymphocyte homing |
| Q37821495 | Acute infusion reactions induced by monoclonal antibody therapy |
| Q38609620 | Advancing drug delivery systems for the treatment of multiple sclerosis |
| Q31002774 | An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis |
| Q42150376 | Anti-integrin therapy for multiple sclerosis |
| Q35637379 | Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases |
| Q34801034 | Asymptomatic reactivation of JC virus in patients treated with natalizumab |
| Q74441679 | Barrier to electrical storms |
| Q30486061 | Beta1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity |
| Q28243054 | Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance |
| Q37113435 | CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia |
| Q87453680 | CD84 is markedly up-regulated in Kawasaki disease arteriopathy |
| Q30541389 | CXCL12-induced monocyte-endothelial interactions promote lymphocyte transmigration across an in vitro blood-brain barrier |
| Q33370950 | Choice of early and escalation treatment options for multiple sclerosis |
| Q53238466 | Clinical and radiological control of highly active relapsing-remitting multiple sclerosis with first-line natalizumab. |
| Q51146514 | Cost-effectiveness of natalizumab in multiple sclerosis |
| Q35212994 | Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis |
| Q29010983 | Current and emerging therapies in multiple sclerosis: a systematic review |
| Q36506677 | Current and future immunomodulation strategies to restore tolerance in autoimmune diseases |
| Q37855719 | Current disease-modifying treatment of multiple sclerosis |
| Q35613492 | Cutting edge: loss of α4 integrin expression differentially affects the homing of Th1 and Th17 cells |
| Q35154391 | Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination. |
| Q37195453 | Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation. |
| Q50086043 | ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphat |
| Q36905624 | Ectonucleotidase activity and immunosuppression in astrocyte-CD4 T cell bidirectional signaling. |
| Q37180600 | Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function |
| Q38315992 | Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs |
| Q33373995 | Effects of natalizumab treatment on Foxp3+ T regulatory cells |
| Q44801255 | Emerging aspects of leukocyte migration. |
| Q91705602 | Eosinophilic Pneumonia Associated With Natalizumab In A Patient With Multiple Sclerosis: A Case Report And Literature Review |
| Q31104121 | Epstein-Barr virus peptide presented by HLA-E is predominantly recognized by CD8(bright) cells in multiple sclerosis patients |
| Q37154788 | FTY720 (fingolimod) for relapsing multiple sclerosis. |
| Q38592449 | Factors controlling permeability of the blood-brain barrier |
| Q34618474 | Fingolimod for relapsing multiple sclerosis: an update. |
| Q37152701 | Hallmarks of Tissue-Resident Lymphocytes |
| Q42413795 | Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study |
| Q50984779 | Herpes encephalitis during natalizumab treatment in multiple sclerosis |
| Q37072894 | Identification of a metabolizing enzyme in human kidney by proteomic correlation profiling |
| Q24597369 | Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine |
| Q36151968 | Immune modulating peptides for the treatment and suppression of multiple sclerosis |
| Q37823315 | Innovative monoclonal antibody therapies in multiple sclerosis |
| Q34975230 | Integrin alpha L controls the homing of regulatory T cells during CNS autoimmunity in the absence of integrin alpha 4. |
| Q37182906 | Involvement of calpain in the process of Jurkat T cell chemotaxis |
| Q33607919 | Is Decompressive Surgery for Cervical Spondylotic Myelopathy Effective in Patients Suffering from Concomitant Multiple Sclerosis or Parkinson's Disease? |
| Q35005863 | JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals |
| Q82412149 | JCV detection in multiple sclerosis patients treated with natalizumab |
| Q38009359 | Leucocyte recruitment in inflammation and novel endogenous negative regulators thereof |
| Q26822941 | Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease |
| Q35091388 | Loss of T cell CD98 H chain specifically ablates T cell clonal expansion and protects from autoimmunity |
| Q30533919 | Macrophages require Skap2 and Sirpα for integrin-stimulated cytoskeletal rearrangement. |
| Q33670934 | Management of acute exacerbations in multiple sclerosis. |
| Q37583874 | Measuring Brain Tissue Integrity during 4 Years Using Diffusion Tensor Imaging. |
| Q36445393 | Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. |
| Q37968620 | Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. |
| Q37814815 | Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges |
| Q26826930 | Multiple sclerosis-a quiet revolution |
| Q38801813 | Multiple sclerosis: genetics, biomarkers, treatments |
| Q34342662 | Multiple sclerosis: overview of disease-modifying agents |
| Q46736492 | Myocardial ischaemia-reperfusion injury in haematopoietic cell-restricted beta1 integrin knockout mice |
| Q24235861 | Natalizumab for relapsing remitting multiple sclerosis |
| Q84465852 | Natalizumab in the treatment of multiple sclerosis |
| Q36568666 | Natalizumab therapy for multiple sclerosis |
| Q39048568 | Natalizumab treatment of multiple sclerosis: new insights |
| Q36748702 | New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come |
| Q44117548 | New approaches to drug safety: a pharmacovigilance tool kit. |
| Q82961967 | New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab |
| Q26784619 | Novel Insights and Therapeutics in Multiple Sclerosis |
| Q37614638 | Novel targeted therapies for autoimmunity |
| Q37804830 | Optimizing therapeutic antibody function: progress with Fc domain engineering |
| Q90230131 | Oxysterols in Autoimmunity |
| Q30987183 | PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER. |
| Q82709313 | PML risk and natalizumab: more questions than answers |
| Q36055389 | Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis |
| Q84431039 | Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals |
| Q35701501 | Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project |
| Q40466907 | Prophylactic Effect of BIO-1211 Small-Molecule Antagonist of VLA-4 in the EAE Mouse Model of Multiple Sclerosis. |
| Q35107430 | Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes |
| Q38211955 | Quality of life outcomes following surgery for patients with coexistent cervical stenosis and multiple sclerosis. |
| Q34997869 | Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies |
| Q90314792 | RNA-Binding Protein HuR Promotes Th17 Cell Differentiation and Can Be Targeted to Reduce Autoimmune Neuroinflammation |
| Q30962193 | Recent developments in multiple sclerosis therapeutics |
| Q37068900 | Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis |
| Q91884302 | Regulation of lymphocyte trafficking in central nervous system autoimmunity |
| Q34231394 | Remitting-relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab |
| Q37235715 | Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| Q34520871 | Suppression of neuro inflammation in experimental autoimmune encephalomyelitis by glia maturation factor antibody |
| Q37976344 | Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence |
| Q38098493 | Targeting cells in motion: migrating toward improved therapies |
| Q36775309 | Targeting endothelial CD146 attenuates neuroinflammation by limiting lymphocyte extravasation to the CNS. |
| Q38035711 | The anatomical and cellular basis of immune surveillance in the central nervous system. |
| Q38798668 | The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis |
| Q36187755 | The mesenchymal tumor microenvironment: a drug-resistant niche |
| Q38257410 | The role of integrin antagonists in the treatment of inflammatory bowel disease |
| Q37536053 | The role of natalizumab in hematopoietic stem cell mobilization |
| Q38089599 | The role of natural killer cells in multiple sclerosis and their therapeutic implications |
| Q33700752 | The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy |
| Q37715703 | The safety and side effects of monoclonal antibodies |
| Q38883237 | The safety of treatment options for pediatric Crohn's disease |
| Q39472801 | The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications |
| Q34763184 | Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina |
| Q30965003 | Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. |
| Q35163712 | Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism |
| Q84367880 | [Intravenous immunoglobulins in multiple sclerosis. An update] |
| Q83630544 | [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy] |
| Q30488236 | alpha4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions |
Search more.